|
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Neuropsychiatric Effects of Interferon-Alpha and Ribavirin conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Neuropsychiatric Effects of Interferon-Alpha and Ribavirin Clinical research trials and Neuropsychiatric Effects of Interferon-Alpha and Ribavirin healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Neuropsychiatric Effects of Interferon-Alpha and Ribavirin. Neuropsychiatric Effects of Interferon-Alpha and Ribavirin Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Neuropsychiatric Effects of Interferon-Alpha and Ribavirin clinical trial. Human subjects often obtain the finest healthcare possible for their Neuropsychiatric Effects of Interferon-Alpha and Ribavirin condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "N" Clinical Trials Conditions > Neuropsychiatric Effects of Interferon-Alpha and Ribavirin  Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
For Condition: Mental Disorder
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Use of the drug interferon-alpha (IFN-A), is associated with frequent and well characterized side effects like neurotoxicity. Neurotoxicity can cause symptoms of depression, agitation, anxiety, and/or confusion. The NIDDK is conducting a research study called, "Combination of Alpha Interferon with Long Term Ribavirin Therapy for Patients with Chronic Hepatitis C" (98-DK-0003). Patients participating in it are receiving interferon-alpha in addition to an antiviral medication called ribavirin. Researchers at the NIMH intend to study patients to learn more about how different medications can influence mood, thoughts and behavior. The primary purpose of this study is to determine if treatment with IFN-A in combination with ribavirin alters human brain biochemistry as measured by proton magnetic resonance spectroscopy (MRS). MRS uses strong magnetic fields in order to measure biochemical products of metabolism found in the brain. Researchers intend to perform MRS scans before, during, and after patients receive their medications Researchers believe that the combination of IFN-A/Ribavirin will directly affect specific areas of the brain and as a result, some patients will develop specific mood or cognitive symptoms. Patients often must stop taking these medications because of the side effects. This study will not contribute directly to the treatment of patient's Hepatitis C condition. However, the information gathered from this study will help researchers better understand the neuropsychiatric affects associated with interferon alpha and ribavirin therapy.
Details: The systemic administration of interferon-alpha (IFN-A) is associated with frequent and well characterized neuropsychiatric toxicity. The primary purpose of this study is to determine if treatment with IFN-A in combination with ribavirin alters human brain biochemistry as measured by proton magnetic resonance spectroscopy. The study population will be drawn from subjects simultaneously enrolled in a NIDDK protocol (98-DK-0003) that employs IFN-A and ribavirin for the treatment of hepatitis C virus (HCV) infection. Subjects will be evaluated prior to IFN-A/ribavirin treatment and then followed prospectively with the specific aim of identifying the emergence of central nervous system (CNS) effects. The principal outcome measures will be as follows: determinations of specific brain metabolites as measured by proton magnetic resonance spectroscopy (1H-MRS), a brief, non-invasive, and minimal risk procedure; ratings of mood, cognitive, and behavioral symptoms. The hypotheses being tested in this study are as follows: 1) Treatment with IFN-A/ribavirin will decrease measures of neuronal integrity (NAA/CRE ratio) in a brain region specific fashion. 2) The degree of change in NAA/CRE in certain brain regions (e.g. prefrontal cortex) will correspond to the development of mood or cognitive symptoms. The questions being asked in this study are relevant to the clinical management of HCV patients, since adverse neuropsychiatric effects of IFN-A and ribavirin frequently complicate protocol participation and occasionally result in a subject being taken off protocol. There are no anticipated number of patient days per year required for this study, as all participants will be simultaneously enrolled in NIDDK protocol 98-DK-0003.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Subjects must be at least 18 years of age. Subjects eligible for this study will be those enrolled in NIDDK protocol 98-DK-0003 and consequently at increased risk for the development of neuropsychiatric toxicity. Subjects must be able to provide informed consent. No individuals who are critically ill or markedly agitated or confused. No individuals with implanted cardiac pacemakers or autodefibrillators. No individuals with implanted neural pacemakers. No individuals with CNS aneurysmal clips. No individuals with cochlear implants. No individuals with metallic foreign bodies in the eye or CNS. No individuals with any form of implanted wire or metal device which may concentrate radiofrequency fields. No pregnant women. No individuals with a history of moderate to severe claustrophobia.
Total Enrollment: 150
Location and Contact Information:
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 960103; 96-M-0103
Study Start Date: June 20, 1996
Record last reviewed: June 13, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001547
Other Mental Disorder Studies:
1. Consequences of Conjugal Bereavement in Adults
2. Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers
3. Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated with Streptococcal Infections
4. I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
5. Neuropsychiatric Evaluation of Healthy Volunteers and Adults with Schizophrenia
Related Studies:
Other Mental Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Neuropsychiatric Effects of Interferon-Alpha and Ribavirin
|
|
|
|
|
|
|
|
